Clinical research update: Zoledronate

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1699-1701

  Body, J J ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL MODEL; BONE METASTASIS; BREAST CARCINOMA; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030749323     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1699::aid-cncr23>3.0.co;2-u     Document Type: Conference Paper

References (4)

1. Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996;22:265-87.
2. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-50.
3. Body JJ, Ford JM, Vigneron AM, et al. A dose finding study of zoledronate intravenous infusion in patients with tumour induced hypercalcemia. J Bone Miner Res 1996;11(Suppl 1): S485.
4. Berenson JR, Lipton A, Rosen LS, et al. Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases. Blood 1996;88(Suppl 1): 586a